ANGPTL3 (F8N1Q) Rabbit mAb #26533
- WB
Supporting Data
| REACTIVITY | H |
| SENSITIVITY | Endogenous |
| MW (kDa) | 30-38, 55-65 |
| Source/Isotype | Rabbit IgG |
Application Key:
- WB-Western Blotting
Species Cross-Reactivity Key:
- H-Human
Product Information
Product Usage Information
| Application | Dilution |
|---|---|
| Western Blotting | 1:1000 |
| Simple Western™ | 1:10 - 1:50 |
Storage
Protocol
Specificity / Sensitivity
ANGPTL3 (FN1Q) Rabbit mAb recognizes endogenous levels of total ANGPTL3 protein. This antibody recognizes both the full-length protein (UniProt #Q9Y5C1) and the cleaved C-terminal fibrinogen-like domain (ANGPTL3-FLD).
Species Reactivity:
Human
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human ANGPTL3 protein.
Background
Angiopoietin-like 3 (ANGPTL3) is a secreted protein primarily expressed in liver and a regulator of fatty acid homeostasis (1). The angiopoietin-like family contains a signal peptide, an N-terminal coiled-coil domain (CCD), a linker peptide, and a C-terminal fibrinogen-like domain (FLD). Cleavage of the CCD and FLD occurs within the linker peptide, and is required for the activity of both domains (2). ANGPTL3-CCD, in concert with ANGPTL4/ANGPTL8, increases circulating triglyceride levels by inhibiting lipoprotein lipase, a hydrolase of LDL cholesterol (2,3). ANGPTL3-CCD also directly inhibits endothelial lipase, the enzyme responsible for HDL cholesterol hydrolysis (8,9). Thus, ANGPTL3-deficient mice have low levels of plasma HDL cholesterol, a risk factor for atherosclerosis (8,9). Unlike traditional angiopoietins, ANGPTL3-FLD does not bind the Tie2 receptor (4). ANGPTL3-FLD has been demonstrated to stimulate angiogenesis in endothelial cells via binding to integrin αVβ3, and to facilitate lipolysis in adipocytes via stimulation of the PDGFRβ-BRAF-ERK pathway (4,5). ANGPTL3 is currently a therapeutic target in patients with high-LDL dyslipidaemia, and can be inhibited with the use of monoclonal antibodies or antisense nucleotides (6,7).
- Conklin, D. et al. (1999) Genomics 62, 477-82.
- Ono, M. et al. (2003) J Biol Chem 278, 41804-9.
- Zhang, R. (2016) Open Biol 6, 150272.
- Camenisch, G. et al. (2002) J Biol Chem 277, 17281-90.
- Bini, S. et al. (2022) Biomolecules 12, 585. doi: 10.3390/biom12040585.
- Lim, G.B. (2017) Nat Rev Cardiol 14, 381.
- Wiegman, A. et al. (2023) Circulation, doi: 10.1161/CIRCULATIONAHA.123.065529.
- Shimamura, M. et al. (2007) Arterioscler Thromb Vasc Biol 27, 366-72.
- Sylvers-Davie, K.L. et al. (2021) J Lipid Res 62, 100112.
Limited Uses
Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.